Equities research analysts expect Thermo Fisher Scientific Inc. (NYSE:TMO) to report sales of $5.62 billion for the current quarter, Zacks reports. Seven analysts have made estimates for Thermo Fisher Scientific’s earnings. The lowest sales estimate is $5.54 billion and the highest is $5.67 billion. Thermo Fisher Scientific reported sales of $4.77 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 17.8%. The business is expected to issue its next earnings results on Wednesday, April 25th.
According to Zacks, analysts expect that Thermo Fisher Scientific will report full-year sales of $5.62 billion for the current year, with estimates ranging from $23.47 billion to $23.67 billion. For the next fiscal year, analysts forecast that the company will report sales of $24.82 billion per share, with estimates ranging from $24.49 billion to $25.95 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Thermo Fisher Scientific.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.66 by $0.13. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter last year, the company posted $2.41 earnings per share. The firm’s quarterly revenue was up 22.1% compared to the same quarter last year.
In other news, SVP Gregory J. Herrema sold 33,327 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $219.70, for a total value of $7,321,941.90. Following the completion of the transaction, the senior vice president now directly owns 60,471 shares in the company, valued at $13,285,478.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $204.60, for a total transaction of $511,500.00. The disclosure for this sale can be found here. Insiders have sold 88,827 shares of company stock valued at $19,012,672 in the last quarter. Company insiders own 0.49% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Chemical Bank lifted its position in Thermo Fisher Scientific by 17.4% during the fourth quarter. Chemical Bank now owns 14,485 shares of the medical research company’s stock valued at $2,751,000 after purchasing an additional 2,148 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in Thermo Fisher Scientific by 16.4% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 12,330 shares of the medical research company’s stock valued at $2,341,000 after purchasing an additional 1,737 shares during the last quarter. D.B. Root & Company LLC bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $213,000. KCM Investment Advisors LLC lifted its position in Thermo Fisher Scientific by 28.8% during the fourth quarter. KCM Investment Advisors LLC now owns 3,883 shares of the medical research company’s stock valued at $737,000 after purchasing an additional 869 shares during the last quarter. Finally, Xact Kapitalforvaltning AB lifted its position in Thermo Fisher Scientific by 6.8% during the fourth quarter. Xact Kapitalforvaltning AB now owns 85,954 shares of the medical research company’s stock valued at $16,321,000 after purchasing an additional 5,509 shares during the last quarter. Institutional investors own 87.67% of the company’s stock.
NYSE TMO traded up $0.54 during trading hours on Tuesday, reaching $206.46. 1,787,684 shares of the company were exchanged, compared to its average volume of 1,455,100. Thermo Fisher Scientific has a 1 year low of $151.74 and a 1 year high of $226.44. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.34. The company has a market capitalization of $82,952.33, a PE ratio of 21.76, a price-to-earnings-growth ratio of 1.51 and a beta of 1.15.
The firm also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date is Wednesday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 7.17%.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.